Immorta Bio's Innovative Approach to Cancer Treatment
Harnessing Natural Killer Cells to Combat Cancer
Immorta Bio SenoVax™ Senolytic Cancer Immunotherapy Boosts Multiple Arms of the Immune System
Immorta Bio Inc, a pioneering scientific longevity company dedicated to advancing aging therapies, recently presented significant laboratory findings that reflect on the potential of their proprietary immunotherapy products. These findings showcased how the reduction of senescent cells results in a robust increase in the numbers and activity of natural killer (NK) cells, essential components of the immune system crucial for combating cancer and viral infections.
The Science Behind SenoVax™
Sigificant advancements have been made with Immorta Bio’s SenoVax™ immunotherapy, which has been shown to effectively reduce senescent cells. The therapy also enhances the efficacy of checkpoint inhibitors and standard chemotherapy agents and stimulates the regenerative properties of endogenous stem cells, particularly observed in rat models. The focus of this therapy is now explicitly toward the treatment of lung cancer, demonstrating a strategic alignment with current oncological challenges.
Importance of Natural Killer Cells
Natural killer cells are pivotal in the body’s defense against malignancies and pathogens. Research indicates a strong correlation between the density of NK cells infiltrating tumors and improved survival rates across various cancer types, such as breast, lung, brain, and pancreatic cancers. Moreover, enhanced NK cell activity has been linked to a greater capability to resist viral infections, underscoring their role in overall immune health.
Insights from Leadership
"Aging increases the risk of cancer and susceptibility to viral attacks, a fact well documented in scientific literature. Preliminary data suggests that mitigating the burden of senescent cells through either conventional senolytic therapies or our innovative SenoVax™ treatment enhances the production and functionality of NK cells. This augmentation may indeed contribute to a reduced likelihood of developing cancer and viral infections," remarked Thomas Ichim, Ph.D., the President and CSO of Immorta Bio.
Transferability of Enhanced Immunity
Interestingly, recent experiments in animal models have demonstrated not only an increase in NK cell activity but also the potential for these enhanced cells to be transferred between naïve animals, leading to tumor eradication. This exciting finding emphasizes the need for further research on how SenoVax can train NK cells to effectively target and eliminate cancer cells—an ability that could someday be leveraged across species.
A Unique Approach to Cancer Treatment
"SenoVax therapy is a natural method for enhancing the body's inherent capabilities to fight cancer," stated Dr. Boris Reznik, the CEO and Chairman of Immorta Bio. This innovative methodology focuses on dismantling the "senescent shield" that tumors use for self-protection. SenoVax can function as a standalone therapy or as a supplementary treatment alongside existing therapies that currently cater to only a fraction of cancer patients.
About Immorta Bio
Immorta Bio Inc. is committed to tackling the complexities associated with aging by addressing diseases linked to age progression. By developing advanced anti-aging technologies, Immorta Bio aims to confront significant medical challenges—including advanced cancers and other age-related conditions. For more details on their research endeavors, interested readers can explore avenues through their official website or connect via social media platforms.
Company Contact
Dr. Boris Reznik
Immorta Bio
https://www.immortabio.com
+1 305-632-2939
@immortabio
Frequently Asked Questions
What is SenoVax™?
SenoVax™ is an innovative senolytic immunotherapy developed by Immorta Bio that aims to reduce senescent cells to improve immune cell functionality.
How do NK cells work?
Natural killer cells are vital components of the immune system that help recognize and destroy cancer cells and virally infected cells.
Why are senescent cells harmful?
Senescent cells can contribute to various age-related diseases, including cancer, by creating an environment that promotes disease progression.
What sets Immorta Bio apart from other companies?
Immorta Bio focuses on treating aging as a disease, developing therapies that empower the immune system, unlike traditional approaches that primarily target diseases after they occur.
Is SenoVax™ available to patients now?
SenoVax™ is still under development, specifically targeted at lung cancer, and is not currently available for commercial use.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
